Expert Interview
A Conversation on the Chronic Urticaria Landscape
Ticker(s): CLDX, NVS, RHHBFInstitution: University of Rochester
- Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
- Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
- Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.
Please tell us about your clinical experience. How many patients
with dermatological issues do you treat on a yearly basis, what is the
typical therapy choice for chronic urticaria patients?
Walk us through your treatment algorithm. How many patients move onto biologics?
How likely would you be to use Ligelizumab (QGE031) in your patients? Will this majorly disrupt usage of Xolair?
Where does a therapy like CDX-0159 fit into the current paradigm?
Any other exciting modalitis? Do you view BTKs as a real threat or is the tolerability going to be a major question?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
